Elanix Biotechnologies AG (FRA:ELN) Total Stockholders Equity : €-1.40 Mil (As of Dec. 2018)

View and export this data going back to . Start your Free Trial

What is Elanix Biotechnologies AG Total Stockholders Equity?

Elanix Biotechnologies AG's Total Stockholders Equity for the quarter that ended in Dec. 2018 was €-1.40 Mil. It refers to the net assets owned by shareholders. It does not include minority interest.

Total Stockholders Equity is used to calculate Book Value per Share. Elanix Biotechnologies AG's Book Value per Share for the quarter that ended in Dec. 2018 was €-0.17. The ratio of a company's debt over equity can be used to measure how leveraged this company is. Elanix Biotechnologies AG's Debt-to-Equity for the quarter that ended in Dec. 2018 was 0.00.

Elanix Biotechnologies AG Total Stockholders Equity Historical Data

The historical data trend for Elanix Biotechnologies AG's Total Stockholders Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Elanix Biotechnologies AG Total Stockholders Equity Chart

Elanix Biotechnologies AG Annual Data

Trend

Dec09

Dec10

Dec11

Dec12

Dec13

Dec14

Dec15

Dec16

Dec17

Dec18

Total Stockholders Equity

Get a 7-Day Free Trial

0.26

16.08

15.43

0.54

-1.40

Elanix Biotechnologies AG Semi-Annual Data
	Dec08	Dec09	Jun10	Dec10	Jun11	Dec11	Jun12	Dec12	Jun13	Dec13	Jun14	Dec14	Jun15	Dec15	Jun16	Dec16	Jun17	Dec17	Jun18	Dec18
Total Stockholders Equity	Get a 7-Day Free Trial															15.43	18.10	0.54	15.25	-1.40

Elanix Biotechnologies AG (FRA:ELN) Total Stockholders Equity Explanation

1. Total Stockholders Equity is used to calculate Book Value per Share.

Elanix Biotechnologies AG's Book Value per Share for the quarter that ended in Dec. 2018 is

Book Value per Share	=	(Total Stockholders Equity	-	Preferred Stock)	/	Shares Outstanding (EOP)
	=	(-1.403	-	0)	/	8.0809
	=	-0.17

2. The ratio of a company's debt over equity can be used to measure how leveraged this company is.

Elanix Biotechnologies AG's Debt-to-Equity for the quarter that ended in Dec. 2018 is

Debt-to-Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(0	+	0)	/	-1.403
	=	0.00

Elanix Biotechnologies AG Total Stockholders Equity Related Terms

Thank you for viewing the detailed overview of Elanix Biotechnologies AG's Total Stockholders Equity provided by GuruFocus.com. Please click on the following links to see related term pages.

Elanix Biotechnologies AG (FRA:ELN) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Elanix Biotechnologies AG (FRA:ELN) » Definitions » Total Stockholders Equity

Comparable Companies

Traded in Other Exchanges

N/A

Address

Street-4, Georg-Glock, c/o HEUKING KÜHN LÜER WOJTEK, Dusseldorf, NW, DEU, 40474

Website

https://www.elanixbiotechnologies.ch

Elanix Biotechnologies AG is a tissue regeneration company. It develops and commercializes products for acute wound care, dermatological and gynecological applications as well as providing cell technology services. The company's operating segment include Regenerative Medicine and Cosmetic ointments. It generates maximum revenue from the Cosmetic ointments segment. Geographically, it derives a majority of revenue from Switzerland and also has a presence in the EU, and Taiwan.

Elanix Biotechnologies AG (FRA:ELN) Headlines

No Headlines